Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Fineline Cube Apr 30, 2026
Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

Fineline Cube Apr 30, 2026
Company Digital

DeepSeek Enhances Biopharma IND and NDA Processes with AI

Fineline Cube Jan 29, 2025

In the regulatory submissions for Investigational New Drug (IND) and New Drug Application (NDA) in...

Company Drug

Enhertu Approved by FDA for HR-Positive, HER2-Low Breast Cancer

Fineline Cube Jan 29, 2025

Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) jointly announced that their co-developed antibody-drug...

Company

Vigonvita Life Sciences Targets HKEX IPO with Integrated Biopharma Model

Fineline Cube Jan 28, 2025

On January 27, 2025, the Hong Kong Stock Exchange (HKEX) website displayed that Suzhou Vigonvita...

Company Deals

CStone Pharmaceuticals Partners with SteinCares for Sugemalimab Commercialization in Latin America

Fineline Cube Jan 27, 2025

CStone Pharmaceuticals (HKG: 2616), a China – based biopharmaceutical company focused on oncology drug development,...

Company Medical Device

MicroPort’s Fireliums Receives NMPA Approval for Coronary Bifurcation Stenosis Treatment

Fineline Cube Jan 27, 2025

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced receiving marketing approval from...

Company Medical Device

MicroPort’s TomaHawk Intravascular Shock Wave Therapy Device Approved by NMPA

Fineline Cube Jan 27, 2025

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced receiving marketing approval from...

Company Drug

FDA Clears sBLA for Eisai and Biogen’s Leqembi Maintenance Dosing

Fineline Cube Jan 27, 2025

Partners Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have announced that the...

Company Deals Medical Device

Jiangsu Yuyue Partners with Inogen for International Distribution and R&D

Fineline Cube Jan 27, 2025

China-based Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (SHE: 002223) has struck a partnership...

Company Drug

Guangzhou Innogen’s Efsubaglutide Alfa Approved by NMPA for Type 2 Diabetes

Fineline Cube Jan 27, 2025

China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd, a biopharma focused on metabolic diseases, has announced...

Company Drug

MSD and Eisai’s Keytruda/Lenvima Combo Shows Promise in Gastroesophageal Cancer Study

Fineline Cube Jan 26, 2025

Partners Merck, Sharp & Dohme (MSD, NYSE: MRK) and Eisai (TYO: 4523) have announced the...

Policy / Regulatory

NHSA Targets Low-Volume Drugs in National Reimbursement List

Fineline Cube Jan 26, 2025

The National Healthcare Security Administration (NHSA) in China has released a list of 131 drugs...

Company Drug

Novo Nordisk’s Amycretin Shows Promising Weight Loss Results in Phase Ib/IIa Study

Fineline Cube Jan 26, 2025

Denmark – based pharmaceutical giant Novo Nordisk A / S (NYSE: NVO) has announced topline...

Company Deals

Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing

Fineline Cube Jan 26, 2025

Jiangsu Vcare PharmaTech Co., Ltd., a China – based high – tech pharmaceutical company, has...

Company Deals

GeneQuantum Secures $13 Billion Deals with Biohaven and AimedBio for ADC Development

Fineline Cube Jan 26, 2025

Suzhou based biotech firm GeneQuantum has announced a series of major commercial cooperation pacts worth...

Company Deals

Sinopharm Partners with Biogen for Comprehensive Service Agreement

Fineline Cube Jan 26, 2025

China-based Sinopharm Group Co., Ltd (HKG: 1099) has entered into a strategic partnership with US-based...

Company Drug

Boehringer Ingelheim’s Nerandomilast Granted Priority Review for IPF in China

Fineline Cube Jan 26, 2025

German pharmaceutical giant Boehringer Ingelheim has announced that the Center for Drug Evaluation (CDE) of...

Company Deals

Mirxes Holding Files for Hong Kong IPO with Focus on miRNA Test Kits

Fineline Cube Jan 26, 2025

Mirxes Holding Company Ltd, a Singapore – headquartered RNA technology company, has received a filing...

Company Drug

Shenzhen Kangtai Halts COVID-19 Vaccine Development Amid Market Shifts

Fineline Cube Jan 26, 2025

Shenzhen based biopharmaceutical company Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the...

Company Medical Device

Huadong Medicine’s Ellansé M Filing Accepted by China’s NMPA

Fineline Cube Jan 26, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that its market filing for the...

Company Digital Drug

China Medical System Partners with MabGeek for Innovative Drug MG-K10

Fineline Cube Jan 26, 2025

China Medical System Holdings (CMS; HKG: 0867) has announced a new license agreement with MabGeek...

Posts pagination

1 … 214 215 216 … 660

Recent updates

  • BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer
  • Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength
  • Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer
  • Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam
  • AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Company

Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength

Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.